XOLAIR 150 mg, solution for injection in a pre-filled pen syringe, 1 ml
Active ingredients: Omalizumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 1 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- XOLAIR 150 mg, solution injectable en stylo prérempli
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue préremplie en verre de 1 ml dans stylo pré-rempli
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Oct 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65161930CIP73028116CIP133400930281161Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| OMALIZUMABsolution | 150 mg · une stylo prérempli de 1 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.